stockrowAMNEAL PHARMACEUTICALS, INC.
AMRX Healthcare Drug Manufacturers Specialty & Generic
AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.
- Revenue
- +9.96%
- EPS
- +267.0%
- Free cash flow
- −50.9%
- Total debt
- +23.8%
Quarter to September 2026, against a year earlier
Follow AMRX
Alert me
AMNEAL PHARMACEUTICALS, INC. (AMRX) Free cash flow
AMNEAL PHARMACEUTICALS, INC.'s free cash flow for fiscal 2025 was $227.7M, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was −$60.5M. Over the past ten years it has ranged from −$95.7M (fiscal 2019) to $312.8M (fiscal 2020); the current reading is higher than 82% of that period. AMNEAL PHARMACEUTICALS, INC. ranks 77th of 84 Drug Manufacturers Specialty & Generic companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $227.7M | 3.46% |
| FY2024 | $220.1M | (20.36%) |
| FY2023 | $276.4M | — |
| FY2022 | −$25.5M | — |
| FY2021 | $194.2M | (37.92%) |
| FY2020 | $312.8M | — |
| FY2019 | −$95.7M | — |
| FY2018 | $178.5M | 48.84% |
| FY2017 | $119.9M | — |
| FY2016 | −$9.5M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $47.1M | — |
| Jun 2026 | −$144.0M | — |
| Mar 2026 | −$48.5M | — |
| Dec 2025 | $84.9M | (11.59%) |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| LNTH Lantheus Holdings, Inc. compare | $409.5M |
| ELAN Elanco Animal Health Incorporated compare | $379.0M |
| ALKS Alkermes plc compare | $228.4M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $197.2M |
| LQDA Liquidia Corporation compare | $150.7M |
| RDY Dr. Reddy's Laboratories Ltd compare | $96.0M |
| HIMS Hims & Hers Health, Inc. compare | $83.0M |
| SUPN Indivior Pharmaceuticals Inc. compare | $31.0M |
| AMRX AMNEAL PHARMACEUTICALS, INC. | −$60.5M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on AMRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement